CarcinomaPhase 2NCT05283226
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
A Phase 2 study testing NRC-2694-A and Paclitaxel in people with Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, run by NATCO Pharma Ltd. at 13 sites in 2 countries.
Trial summary
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- What is being tested?
- NRC-2694-A and Paclitaxel
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 13 sitesin 2 countries
- Study dates
- 30 Sep 2022to 30 Jun 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Is willing and capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
- Is male or female aged 18 years or older at the time of consent.
- Has histologically confirmed unresectable R/M HNSCC (oral cavity, oropharynx, hypopharynx, and larynx).
- Has documented progressive disease assessed by the principal investigator according to RECIST v1.1.
- Has a measurable lesion per RECIST v1.1.
- Has ECOG performance status score of ≤2.
Show all 11Show fewer
- Must have progressed during or after receiving ICI therapy, such as pembrolizumab or nivolumab. Patients with prior immune-mediated reactions due to ICI therapies (eg, pembrolizumab or nivolumab) and who had recovered prior to study entry will also be eligible.
- Female patients of childbearing potential should have a negative urine test before enrollment. If the urine pregnancy test is positive or gives equivocal results, a serum pregnancy will be required for confirmation.
- Patients of reproductive age must use acceptable methods of contraception throughout the study period and for 30 days following the last dose of investigational product (see protocol for further guidance).
- During screening and at subsequent visits, the investigator should ensure adequate bone marrow reserve (neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3, and hemoglobin level 8.0 g/dL), renal function (creatinine clearance ≥30 mL/min calculated by Cockcroft-Gault formula), liver function (total bilirubin level ≤1.5 × ULN [except patients with documented Gilbert's syndrome] and serum transaminase levels ≤2.5 × ULN or ≤5 × ULN for liver metastasis and/or obstructive jaundice).
- Must have completed a duration of at least two weeks after stopping ICI therapy/investigational therapy/salvage therapy and must have recovered to grade ≤1 from all toxicities due to such therapies.
Who cannot join
- Has cardiac, hepatic, endocrine, pulmonary, or autoimmune disease, interstitial lung disease, renal or psychiatric disorders, not controlled with therapy corresponding to the illness or a condition that contraindicates the use of a taxane or an EGFR inhibitor.
- Has Cirrhosis of liver at a level of Child-Pugh B (or worse).
- Has uncontrolled brain metastases. Patients are allowed if brain metastasis has been previously treated with surgery, whole brain irradiation, and/or stereotactic radiosurgery and are considered controlled (controlled by the dose ≤10 mg/day of prednisone or equivalent) at the time of the first dose of investigational product. Radiological evaluation of brain metastasis will be performed only if the patient has symptoms. For asymptomatic patients, brain imaging during screening is not required.
- Has baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >480 milliseconds [CTCAE Grade 1] using Fredericia's QT correction formula).
- Has a history of additional risk factors for Torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
- Has had prior cetuximab therapy for recurrent or metastatic disease. Note that cetuximab used concomitantly with radiotherapy or as an induction therapy is acceptable
Show all 20Show fewer
- Has received any other EGFR-targeted therapies for recurrent or metastatic disease.
- Currently participating in any clinical trial or receiving investigational therapy on expanded access or compassionate basis.
- Has nasopharyngeal carcinomas or salivary gland cancers.
- Female patient who tested positive for pregnancy.
- Female patient who is breastfeeding or planning to become pregnant, or male patient planning to father a child within the duration of the study.
- Has tested positive for HIV, HBsAg, HCV antibody, or HCV RNA at screening. However, patients who test positive for HCV antibody, but negative for HCV RNA, will be allowed. In addition, patients with controlled HIV, chronic HBV on suppressive antiviral therapy, or a history of HCV infection status post-curative antiviral treatment with an HCV viral load below limit of quantification are permitted to participate (DHHS 2020).
- Has active infection requiring intravenous anti-infective therapy within 7 days prior to Day 1 Cycle 1 or is febrile due to infection.
- Has had major surgery within 4 weeks prior to screening.
- Administered a live attenuated vaccine within 4 weeks prior to Day 1 Cycle 1 or anticipation that such a live attenuated vaccine will be required during the study.
- Has known or suspected hypersensitivity to any components of the formulation used for this investigational product.
- Has concurrent disease or any clinically significant abnormality following the investigator's review of the screening physical examination findings, 12-lead ECG results, and clinical laboratory tests, which in the judgment of the investigator would interfere with the patient's participation in this study or evaluation of study results.
- Unable to come for study visits per schedule.
- Has current drug or alcohol abuse.
- Has received prior treatment with paclitaxel or docetaxel or any other drugs with taxane like mode of action for recurrent or metastatic or recurrent HNSCC. However, prior paclitaxel or docetaxel or any other drugs with taxane like mode of action as a component of a curatively-intended multimodality treatment for locally advanced HNSCC is permitted.
Trial locations and contacts
13 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
13 sites in 2 countries
United States10 sites
- Completed
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201-1544
- Completed
Lynn Cancer Center
Boca Raton, Florida, 33486
- Completed
Salib Oncology
Easton, Pennsylvania, 18045
- Completed
Providence Medical Foundation -Fullerton
Fullerton, California, 92835
- Completed
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756-1000
- Completed
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, 90017
- Completed
Norton Cancer Institute - Downtown
Louisville, Kentucky, 40202
- Completed
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792
- Completed
Miami Cancer Center
Miami, Florida, 33176
- Completed
Washington University - Siteman Cancer Center
St Louis, Missouri, 63110
India3 sites, 2 recruiting
- Not yet recruiting
Basavatarakam Indo American Cancer Hospital & Research Institute
Hyderabad, Telangana, 500034
M.V.T Krishna Mohan, +9140-23550015, mvtkm@yahoo.com
- Recruiting
Daycare Angels under AOH
Mumbai, Maharashtra, 40001
Suresh Advani, 9122-565-7323, shadvani2000@yahoo.com
- Completed
Grant Medical Foundation Ruby Hall Clinic
Pune, Maharashtra, 411001
About this study
Official title: A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Read the detailed description
Patients with recurrent and/or metastatic unresectable Head and Neck Cancer have a poor prognosis and limited treatment options. Pembrolizumab and Nivolumab, both ICIs (Immune Checkpoint Inhibitors), are approved therapies for this condition. However, no approved treatment options exist for patients who progress on ICI therapies. Hence, there is an unmet medical need post-failure of ICI therapy. NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor. It was discovered and developed by NATCO Pharma Ltd. NRC-2694-A demonstrated response in HNSCC patients in a Phase-I study as a monotherapy. This was further substantiated in a Phase-II study in combination with cisplatin/carboplatin and paclitaxel.
- Being tested
- NRC-2694-A, Paclitaxel
- Keywords
- Carcinoma, Recurrent and/or Metastatic Cancer
- Medical subject headings
- Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NRC-2694-ADrug
300 mg orally once daily
PaclitaxelDrug
175 mg/m² IV infusion over approximately 3 hours
| Study group | Role | What they receive |
|---|---|---|
| NRC-2694-A In Combination with paclitaxel | Experimental | Patients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more. Receives: Drug: NRC-2694-A; Drug: Paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumab
Objective response in terms of CR/PR per RECIST v1.1
Measured: Baseline through approximately up to 24 weeks
Secondary outcomes (19)
Progression-free survival
defined as the interval of time between the date of enrollment to the earliest date of disease progression, as determined by local radiologic assessment per RECIST v1.1, or death due to any cause, whichever occurs first
Measured: Baseline through approximately up to 24 weeks
Overall survival
defined as the time from the date of enrollment to the date of death due to any cause
Measured: Baseline through approximately up to 24 weeks
Duration of response
defined as the time from first confirmed objective response to disease progression
Measured: Baseline through approximately up to 24 weeks
Clinical benefit response
defined as CR + PR + SD for ≥ 6 months
Measured: Baseline through approximately up to 26 weeks
Number of adverse events
Measured: Baseline through approximately up to 24 weeks
Number of participants with abnormal physical examination findings
Symptom-directed physical examination will be conducted to evaluate skin rash, diarrhea, paresthesia, and dyspnea graded according to NCI CTCAE version 5.0.
Measured: Baseline through approximately up to 24 weeks
Number of participants with abnormal vital signs
Clinically significant abnormal blood pressure, heart rate, respiratory rate, and oral body temperature graded according to NCI CTCAE version 5.0.
Measured: Baseline through approximately up to 24 weeks
Assessing safety through ECOG (Eastern Cooperative Oncology Group)
The severity of the AE will be graded according to the NCI CTCAE version 5.0 (NCI Common Terminology Criteria for Adverse Events. The CTCAE displays Grades 1 through Grade 5 with the higher score as worse outcome)
Measured: Baseline through approximately up to 24 weeks
Number of participants with abnormal clinical laboratory tests results
Clinically significant abnormal hematology, biochemistry, coagulation and urinalysis test results graded according to NCI CTCAE version 5.0.
Measured: Baseline through approximately up to 24 weeks
Number of participants with abnormal ECGs (Electrocardiograms)
Clinically significant abnormal ECG findings will be graded per NCI CTCAE version 5.0.
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Cmax (Maximum plasma concentration)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Tmax (time to reach the maximum plasma concentration)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Ctrough (observed trough plasma concentration at the dosing interval tau)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via AUC0-t (area under the concentration-time curve from time zero to the time of last measurable concentration)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via AUC0-τ (area under the concentration-time curve from time zero to the dosing interval tau)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via CL/F (apparent clearance)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Vz/F (apparent volume of distribution)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Rac Cmax (accumulation ratio based on maximum plasma concentration)
Measured: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Rac AUC (accumulation ratio based on area under the concentration-time curve)
Measured: Baseline through approximately up to 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2022
- Study start30 Sep 2022
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 21 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NATCO Pharma Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05283226
- Sponsor's protocol ID
- NAT2694US
- Status last verified
- Jan 2026
- First submitted
- 8 Feb 2022
- Last updated
- 23 Jan 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
- ClinicalTrials.gov ID
- NCT05283226
- Acronym / sponsor ID
- NAT2694US
- Keywords
- Carcinoma, Recurrent and/or Metastatic Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 21 participants (estimated)
- Lead sponsor
- NATCO Pharma Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Sep 2022 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 16 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Detailed description
Patients with recurrent and/or metastatic unresectable Head and Neck Cancer have a poor prognosis and limited treatment options. Pembrolizumab and Nivolumab, both ICIs (Immune Checkpoint Inhibitors), are approved therapies for this condition. However, no approved treatment options exist for patients who progress on ICI therapies. Hence, there is an unmet medical need post-failure of ICI therapy. NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor. It was discovered and developed by NATCO Pharma Ltd. NRC-2694-A demonstrated response in HNSCC patients in a Phase-I study as a monotherapy. This was further substantiated in a Phase-II study in combination with cisplatin/carboplatin and paclitaxel.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NRC-2694-A In Combination with paclitaxel | Experimental | Drug: NRC-2694-A, Drug: PaclitaxelPatients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Is willing and capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
- Is male or female aged 18 years or older at the time of consent.
- Has histologically confirmed unresectable R/M HNSCC (oral cavity, oropharynx, hypopharynx, and larynx).
- Has documented progressive disease assessed by the principal investigator according to RECIST v1.1.
- Has a measurable lesion per RECIST v1.1.
Key exclusion criteria (20 listed)
- Has cardiac, hepatic, endocrine, pulmonary, or autoimmune disease, interstitial lung disease, renal or psychiatric disorders, not controlled with therapy corresponding to the illness or a condition that contraindicates the use of a taxane or an EGFR inhibitor.
- Has Cirrhosis of liver at a level of Child-Pugh B (or worse).
- Has uncontrolled brain metastases. Patients are allowed if brain metastasis has been previously treated with surgery, whole brain irradiation, and/or stereotactic radiosurgery and are considered controlled (controlled by the dose ≤10 mg/day of prednisone or equivalent) at the time of the first dose of investigational product. Radiological evaluation of brain metastasis will be performed only if the patient has symptoms. For asymptomatic patients, brain imaging during screening is not required.
- Has baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >480 milliseconds [CTCAE Grade 1] using Fredericia's QT correction formula).
- Has a history of additional risk factors for Torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NRC-2694-A300 mg orally once daily | Drug | NRC-2694-A In Combination with paclitaxel |
| Paclitaxel175 mg/m² IV infusion over approximately 3 hours | Drug | NRC-2694-A In Combination with paclitaxel |
Primary outcome
To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumab
Time frame: Baseline through approximately up to 24 weeks
Objective response in terms of CR/PR per RECIST v1.1
19 secondary outcomes
Progression-free survival
Time frame: Baseline through approximately up to 24 weeks
Overall survival
Time frame: Baseline through approximately up to 24 weeks
Duration of response
Time frame: Baseline through approximately up to 24 weeks
Clinical benefit response
Time frame: Baseline through approximately up to 26 weeks
Number of adverse events
Time frame: Baseline through approximately up to 24 weeks
Number of participants with abnormal physical examination findings
Time frame: Baseline through approximately up to 24 weeks
Number of participants with abnormal vital signs
Time frame: Baseline through approximately up to 24 weeks
Assessing safety through ECOG (Eastern Cooperative Oncology Group)
Time frame: Baseline through approximately up to 24 weeks
Number of participants with abnormal clinical laboratory tests results
Time frame: Baseline through approximately up to 24 weeks
Number of participants with abnormal ECGs (Electrocardiograms)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Cmax (Maximum plasma concentration)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Tmax (time to reach the maximum plasma concentration)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Ctrough (observed trough plasma concentration at the dosing interval tau)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via AUC0-t (area under the concentration-time curve from time zero to the time of last measurable concentration)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via AUC0-τ (area under the concentration-time curve from time zero to the dosing interval tau)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via CL/F (apparent clearance)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Vz/F (apparent volume of distribution)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Rac Cmax (accumulation ratio based on maximum plasma concentration)
Time frame: Baseline through approximately up to 24 weeks
Plasma PK parameters of NRC-2694-A measured via Rac AUC (accumulation ratio based on area under the concentration-time curve)
Time frame: Baseline through approximately up to 24 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Carcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
13 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing NRC-2694-A and Paclitaxel in people with Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, run by NATCO Pharma Ltd. at 13 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in United States, India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Praveen Myneni, MBBS (+91 40 23547532, drpraveen@natcopharma.co.in), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumab (time frame: Baseline through approximately up to 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.